Altimmune Statistics
Total Valuation
Altimmune has a market cap or net worth of $601.06 million. The enterprise value is $310.80 million.
| Market Cap | 601.06M |
| Enterprise Value | 310.80M |
Important Dates
The last earnings date was Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Altimmune has 194.52 million shares outstanding. The number of shares has increased by 68.90% in one year.
| Current Share Class | 194.52M |
| Shares Outstanding | 194.52M |
| Shares Change (YoY) | +68.90% |
| Shares Change (QoQ) | +49.00% |
| Owned by Insiders (%) | 0.45% |
| Owned by Institutions (%) | 62.48% |
| Float | 164.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19,514.52 |
| Forward PS | n/a |
| PB Ratio | 1.28 |
| P/TBV Ratio | 1.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 10,151.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 26.78, with a Debt / Equity ratio of 0.08.
| Current Ratio | 26.78 |
| Quick Ratio | 26.37 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.92 |
Financial Efficiency
Return on equity (ROE) is -28.87% and return on invested capital (ROIC) is -17.95%.
| Return on Equity (ROE) | -28.87% |
| Return on Assets (ROA) | -17.20% |
| Return on Invested Capital (ROIC) | -17.95% |
| Return on Capital Employed (ROCE) | -19.18% |
| Weighted Average Cost of Capital (WACC) | 5.32% |
| Revenue Per Employee | $544 |
| Profits Per Employee | -$1.61M |
| Employee Count | 57 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.26% in the last 52 weeks. The beta is 0.17, so Altimmune's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -15.26% |
| 50-Day Moving Average | 2.98 |
| 200-Day Moving Average | 3.67 |
| Relative Strength Index (RSI) | 53.64 |
| Average Volume (20 Days) | 4,504,778 |
Short Selling Information
The latest short interest is 50.97 million, so 26.20% of the outstanding shares have been sold short.
| Short Interest | 50.97M |
| Short Previous Month | 51.94M |
| Short % of Shares Out | 26.20% |
| Short % of Float | 31.01% |
| Short Ratio (days to cover) | 11.33 |
Income Statement
In the last 12 months, Altimmune had revenue of $31,000 and -$91.76 million in losses. Loss per share was -$0.73.
| Revenue | 31,000 |
| Gross Profit | -66.69M |
| Operating Income | -98.73M |
| Pretax Income | -91.76M |
| Net Income | -91.76M |
| EBITDA | -98.63M |
| EBIT | -98.73M |
| Loss Per Share | -$0.73 |
Balance Sheet
The company has $326.28 million in cash and $36.02 million in debt, with a net cash position of $290.26 million or $1.49 per share.
| Cash & Cash Equivalents | 326.28M |
| Total Debt | 36.02M |
| Net Cash | 290.26M |
| Net Cash Per Share | $1.49 |
| Equity (Book Value) | 474.21M |
| Book Value Per Share | 2.44 |
| Working Capital | 322.31M |
Cash Flow
In the last 12 months, operating cash flow was -$76.51 million and capital expenditures -$54,000, giving a free cash flow of -$76.56 million.
| Operating Cash Flow | -76.51M |
| Capital Expenditures | -54,000 |
| Depreciation & Amortization | 99,000 |
| Net Borrowing | 20.40M |
| Free Cash Flow | -76.56M |
| FCF Per Share | -$0.39 |
Margins
| Gross Margin | n/a |
| Operating Margin | -318,493.55% |
| Pretax Margin | -296,000.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Altimmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -68.90% |
| Shareholder Yield | -68.90% |
| Earnings Yield | -15.17% |
| FCF Yield | -12.66% |
Analyst Forecast
The average price target for Altimmune is $17.22, which is 457.28% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.22 |
| Price Target Difference | 457.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 296.85% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 14, 2018. It was a reverse split with a ratio of 1:30.
| Last Split Date | Sep 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Altimmune has an Altman Z-Score of 3.35 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.35 |
| Piotroski F-Score | 3 |